Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02667327 · ClinicalTrials.gov registry record · Phase 3
A Study of Granexin Gel in the Treatment of Diabetic Foot Ulcer
A Phase 3 study, sponsored by Xequel Bio.
- Terminated
- Registry status
- Phase 3
- Development phase
- 124
- Enrollment target
NCT02667327: Clinical Trial Phase 3 study, sponsored by Xequel Bio.
NCT02667327 is a Phase 3 study that was terminated before completion, run by Xequel Bio. The registered enrollment target is 124 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (84% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02667327, a Phase 3 study, was terminated before completion, sponsored by Xequel Bio.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 124 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether Granexin gel is safe and effective in the treatment of diabetic foot ulcers.
Interventions
- OTHER Vehicle gel
- DRUG Granexin gel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 124 participants |
| Start Date | 2018-11-21 |
| Est. Completion | 2020-05-27 |
| Phase | Phase 3 |
Why NCT02667327 stopped before completion
NCT02667327 is an interventional study that assigns participants to a tested intervention. The registered 124 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (84% lower).
The record links to 0 conditions, and to 2 interventions - of which Vehicle gel is the first listed.
NCT02667327 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02667327 about?
NCT02667327 is a clinical study titled "A Study of Granexin Gel in the Treatment of Diabetic Foot Ulcer". The purpose of this study is to determine whether Granexin gel is safe and effective in the treatment of diabetic foot ulcers.
What is the current status of trial NCT02667327?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 124 participants. The study started on 2018-11-21. Estimated completion is 2020-05-27.
What interventions are being tested in trial NCT02667327?
The interventions under investigation include: Vehicle gel (OTHER), Granexin gel (DRUG).
Who is sponsoring clinical trial NCT02667327?
This trial is sponsored by Xequel Bio, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02667327's enrollment target sits among peer trials
124 1610th of 2000 higher than 386 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02523014 · 124 participants · Phase 2
Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas
- NCT02670707 · 124 participants · Phase 3
Vinblastine/Prednisone Versus Single Therapy With Cytarabine for Langerhans Cell Histiocytosis (LCH)
- NCT02830724 · 124 participants · Phase 1
Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers
- NCT04748809 · 124 participants · NA
Effect of Anti-inflammatory Diet in Rheumatoid Arthritis
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI